UNSPSC 51386604: Dibucaine/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386604 Dibucaine/hydrocortisone is a Commodity code that shows minimal alignment with recent state and local procurement activity. The single recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS—solicits naloxone and safe drug deactivation systems, products entirely outside the scope of dibucaine/hydrocortisone pharmaceutical compounds. The mismatch suggests either a tagging error in the source data or a code that captures a narrow pharmaceutical ingredient with limited procurement demand at the state and local level. State and local health and community service departments would be the typical issuing bodies for pharmaceutical procurement under this commodity, but the recent opportunity record does not support active solicitation of dibucaine/hydrocortisone products themselves.

Seminole County, Florida posted the only recent opportunity on June 30, 2026, with a response deadline of July 26, 2023 (an apparent date error in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The solicitation is structured as a competitive IFB with a two-year initial term and one-year renewal option, fixed-fee pricing, and potential FEMA funding. The code shows no recent activity in other states or jurisdictions, and the single opportunity provided is misaligned with the commodity's nominal scope. Business development professionals should verify whether the code itself remains active for state and local procurement or whether this represents a data-taxonomy mismatch rather than genuine market opportunity.